Predicting Harms and Benefits in Translational Trials: Ethics,
Evidence, and Uncertainty

1. KimmelmanJ

2010

Gene transfer and the ethics of first-in-human research: lost in

translation.

Cambridge

Cambridge University Press

2. ExtanceA

2010

Alzheimer's failure raises questions about disease-modifying

strategies.

Nat Rev Drug Discov

9

749

751

3. The National Commission for the Protection of Human Subjects of

Biomedical and Behavioural Research

1979

The Belmont report: ethical principles and guidelines for the

protection of human subjects of research.

Bethesda

Department of Health Education and Welfare

4. World Medical Association

1964

Declaration of Helsinki.

Helsinki

18th World Medical Assembly

5. MannH

2010

ASSERT: a standard for the review and monitoring of randomized

clinical trials.

Available: http://www.assert-statement.org/. Accessed 31 January

2011

6. Department of Health and Human Services

2005

Protection of human subjects: criteria for IRB approval of

research.

Title 45 CFR 46.111(a)(1)

1

12

7. LondonAJKimmelmanJEmborgME

2010

Research ethics. Beyond access vs. protection in trials of

innovative therapies.

Science

328

829

830

8. DjulbegovicBKumarASoaresHPHozoIBeplerG

2008

Treatment success in cancer: new cancer treatment successes

identified in phase 3 randomized controlled trials conducted by the National

Cancer Institute-sponsored cooperative oncology groups, 1955 to

2006.

Arch Intern Med

168

632

642

9. KumarASoaresHWellsRClarkeMHozoI

2005

Are experimental treatments for cancer in children superior to

established treatments? Observational study of randomised controlled trials

by the Children's Oncology Group.

BMJ

331

1295

10. SoaresHPKumarADanielsSSwannSCantorA

2005

Evaluation of new treatments in radiation oncology: are they

better than standard treatments?

JAMA

293

970

978

11. GrossCPKrumholzHMVan WyeGEmanuelEJWendlerD

2006

Does random treatment assignment cause harm to research

participants?

PLoS Med

3

e188

doi:10.1371/journal.pmed.0030188

12. KolaILandisJ

2004

Can the pharmaceutical industry reduce attrition

rates?

Nat Rev Drug Discov

3

711

715

13. PangalosMNSchechterLEHurkoO

2007

Drug development for CNS disorders: strategies for balancing risk

and reducing attrition.

Nat Rev Drug Discov

6

521

532

14. Contopoulos-IoannidisDGNtzaniEIoannidisJP

2003

Translation of highly promising basic science research into

clinical applications.

Am J Med

114

477

484

15. van der WorpHBHowellsDWSenaESPorrittMJRewellS

2010

Can animal models of disease reliably inform human

studies?

PLoS Med

7

e1000245

doi:10.1371/journal.pmed.1000245

16. KilkennyCParsonsNKadyszewskiEFestingMFCuthillIC

2009

Survey of the quality of experimental design, statistical

analysis and reporting of research using animals.

PLoS ONE

4

e7824

doi:10.1371/journal.pone.0007824

17. ReynoldsJCRittenbergerJCMenegazziJJ

2007

Drug administration in animal studies of cardiac arrest does not

reflect human clinical experience.

Resuscitation

74

13

26

18. BathPMGrayLJBathAJBuchanAMiyataT

2009

Effects of NXY-059 in experimental stroke: an individual animal

meta-analysis.

Br J Pharmacol

157

1157

1171

19. PhilipMBenatarMFisherMSavitzSI

2009

Methodological quality of animal studies of neuroprotective

agents currently in phase II/III acute ischemic stroke

trials.

Stroke

40

577

581

20. SenaESvan der WorpHBBathPMHowellsDWMacleodM

2010

Publication bias in reports of animal stroke studies leads to

major overstatement of efficacy.

PLoS Biol

8

e1000344

doi:10.1371/journal.pbio.1000344

21. MacleodMRFisherMO'CollinsVESenaESDirnaglU

2009

Good laboratory practice. Preventing introduction of bias at the

bench.

Stroke

40

e50

e52

22. KilkennyCBrowneWCuthillIEmersonMAltmanD

2010

Improving bioscience research reporting: the ARRIVE guidelines

for reporting animal research.

PLoS Biol

8

e1000412

doi:10.1371/journal.pbio.1000412

23. HenleyDBMayPCDeanRASiemersER

2009

Development of semagacestat (LY450139), a functional

gamma-secretase inhibitor, for the treatment of Alzheimer's

disease.

Expert Opin Pharmacother

10

1657

1664

24. American Society of Clinical Oncology

1997

Critical role of phase I clinical trials in cancer

treatment.

J Clin Oncol

15

853

859

25. ChristianMShoemakerD

2002

The investigator's handbook: a manual for participants in

clinical trials of investigational agents sponsored by DCTD,

NCI.

Bethesda

Cancer Therapy Evaluation Program

26. International Conference on Harmonisation of Technical Requirements for

Registration of Pharmaceuticals for Human Use (ICH)

1996

ICH Harmonized Tripartite Guideline.

Guideline for Good Clinical Practice E6(R1)

27. LowensteinPR

2008

A call for physiopathological ethics.

Mol Ther

16

1771

1772

28. IoannidisJPKarassaFB

2010

The need to consider the wider agenda in systematic reviews and

meta-analyses: breadth, timing, and depth of the evidence.

BMJ

341

c4875

29. MangialascheFSolomonAWinbladBMecocciPKivipeltoM

2010

Alzheimer's disease: clinical trials and drug

development.

Lancet Neurol

9

702

716

30. CummingsJ

2010

What can be inferred from the interruption of the semagacestat

trial for treatment of Alzheimer's disease?

Biol Psychiatry

68

876

878

31. HoldenC

2009

Neuroscience. Fetal cells again?

Science

326

358

359

32. KimmelmanJLondonAJRavinaBRamsayTBernsteinM

2009

Launching invasive, first-in-human trials against

Parkinson's disease: ethical considerations.

Mov Disord

24

1893

1901

33. LindvallOKokaiaZ

2010

Stem cells in human neurodegenerative disorders—time for

clinical translation?

J Clin Invest

120

29

40

34. AndersonJAKimmelmanJ

2010

Extending clinical equipoise to phase 1 trials involving

patients: unresolved problems.

Kennedy Inst Ethics J

20

75

98

35. GilmanSKollerMBlackRSJenkinsLGriffithSG

2005

Clinical effects of Abeta immunization (AN1792) in patients with

AD in an interrupted trial.

Neurology

64

1553

1562

36. FeldmanHHDoodyRSKivipeltoMSparksDLWatersDD

2010

Randomized controlled trial of atorvastatin in mild to moderate

Alzheimer disease: LEADe.

Neurology

74

956

964

37. Elan Corporation

2010

Elan and Transition Therapeutics announce topline summary results

of Phase 2 study and plans for Phase 3 for ELND005 (Scyllo-inositol)

[press release]

38. SallowaySSperlingRGilmanSFoxNCBlennowK

2009

A phase 2 multiple ascending dose trial of bapineuzumab in mild

to moderate Alzheimer disease.

Neurology

73

2061

2070

39. WinbladBGiacobiniEFrolichLFriedhoffLTBruinsmaG

2010

Phenserine efficacy in Alzheimer's disease.

J Alzheimers Dis

22

1201

1208

40. GoldMAldertonCZvartau-HindMEggintonSSaundersAM

2010

Rosiglitazone monotherapy in mild-to-moderate alzheimer's

disease: results from a randomized, double-blind, placebo-controlled phase

III study.

Dement Geriatr Cogn Disord

30

131

146

41. GreenRCSchneiderLSAmatoDABeelenAPWilcockG

2009

Effect of tarenflurbil on cognitive decline and activities of

daily living in patients with mild Alzheimer disease: a randomized

controlled trial.

JAMA

302

2557

2564

42. Bellus Health Inc

2008

Neurochem announces results from Tramiprosate (ALZHEMED(TM))

North American Phase III clinical trial

43. MarksWJJrBartusRTSiffertJDavisCSLozanoA

2010

Gene delivery of AAV2-neurturin for Parkinson's disease: a

double-blind, randomised, controlled trial.

Lancet Neurol

9

1164

1172

44. NuttJBurchielKJComellaCLJankovicJLangAE

2003

Randomized, double-blind trial of glial cell line-derived

neurotrophic factor (GDNF) in PD.

Neurology

60

69

73

45. LangAEGillSPatelNKLozanoANuttJG

2006

Randomized controlled trial of intraputamenal glial cell

line-derived neurotrophic factor infusion in Parkinson

disease.

Ann Neurol

59

459

466

46. FreedCRGreenePEBreezeRETsaiWYDuMouchelW

2001

Transplantation of embryonic dopamine neurons for severe

Parkinson's disease.

N Engl J Med

344

710

719

47. OlanowCWGoetzCGKordowerJHStoesslAJSossiV

2003

A double-blind controlled trial of bilateral fetal nigral

transplantation in Parkinson's disease.

Ann Neurol

54

403

414

48. WattsRLFreemanTBHauserRABakayRAEElliasSA

2001

A double-blind, randomised, controlled, multicenter clinical

trial of the safety and efficacy of stereotaxic intrastriatal implantation

of fetal porcine ventral mesencephalic tissue (Neurocelli-PD) vs. imitation

surgery in patients with Parkinson's disease (PD).

Parkinsonism Relat Disord

7

Suppl

S87

49. OlanowCWSternMBSethiK

2009

The scientific and clinical basis for the treatment of Parkinson

disease.

Neurology

72

21 Suppl 4S1

S136